Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | HTR7 | P34969 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6968336 | 0.99 | DRD2 (0.52) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL6960861 | 0.79 | HRH1 (0.53) | DRD2DRD4DRD3HTR1ASIGMAR1 | |
| SCHEMBL24629113 | 0.78 | HTR1A (0.58) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL6958871 | 0.78 | DRD2 (0.50) | DRD2DRD4DRD3HTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL6960646 | 0.78 | HRH1 (0.52) | DRD2DRD4DRD3HTR1ASIGMAR1 | |
| SCHEMBL9155290 | 0.74 | HTR1A (0.58) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL29932017 | 0.74 | HTR1A (0.58) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL23536279 | 0.74 | HTR1A (0.58) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL31232849 | 0.74 | DRD2 (0.71) | DRD2DRD4DRD3HTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL31232826 | 0.73 | HTR1A (0.57) | DRD2DRD4DRD3HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934312-B1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK AS (DK) | 2003-03-19 | — | — | EP | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | claimed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | claimed |
| EP-0934312-B1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK AS (DK) | 2003-03-19 | — | — | EP | disclosed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| US-6133268-A | 1,4-disubstituted piperazines | NOVO NORDISK A/S (DK) | 2000-10-17 | — | — | US | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| US-6040302-A | ANTIINFLAMMATORY AGENTS TREATING RHEUMATOID ARTHRITIS, MIGRAINE OR ITCHING, INSULIN RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS AND AGEING-ASSOCIATED OBESITY | NOVO NORDISK A/S (DK) | 2000-03-21 | — | — | US | disclosed |
| US-6004961-A | ANTIINFLAMMATORY AGENTS, ANALGESICS; NON-INSULIN-DEPENDENT DIABETES; AGE-RELATED OBESITY; DIBENZO(D,G)(1,3,6)DIOXAZOCINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-12-21 | — | — | US | disclosed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | DRD2 2668/4885DRD4 3443/4885DRD3 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.